On March 21, 2017 the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client Biogen, upholding a patent covering the multiple sclerosis drug Tecfidera in an inter partes review requested by the Coalition for Affordable Drugs. This was the Coalition's second failed attempt to invalidate the patent-in-suit. According to the decision, Biogen's experts presented sufficient evidence to demonstrate that a combination of previous patents, a clinical trial, and other prior art would not have made it obvious for an artisan to choose the 480 milligrams per day dosage cited in the patent.
Commentary
May 20, 2026
Award/Ranking
Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award
May 13, 2026
Press Release
Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination
May 11, 2026
Award/Ranking
Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey
May 7, 2026
Announcement
Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International
May 4, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.